Sol-Gel Reports First Quarter 2025 Results
Financial Results for the First Quarter Year Ended March 31st, 2025
Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024.
Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led manufacturing development to support future commercialization of SGT-610, an increase of $0.5 million related to the commercialization of EPSOLAY and TWYNEO in territories outside of the U.S., offset by a decrease of $0.5 million in clinical trial expenses related to SGT-610.
General and administrative expenses were $1.3 million compared to $1.8 million for the same period in 2024. The decrease of $0.5 million was mainly attributed to a decrease in payroll and stock-based compensation expenses due to cost measures being taken in 2024.
Sol-Gel reported a net loss of $8.8 million for the first quarter of 2025 and of $3.2 basic and diluted loss per share, compared to a net loss of $6.3 million and a loss of $2.3 per basic and diluted share for the same period in 2024.
As of March 31, 2025, Sol-Gel had $16.9 million in cash, cash equivalents, and deposits and no marketable securities for a total balance of $16.9 million.
The Company expects its cash resources to fund cash requirements into the first quarter of 2027.
About Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.
The Company's pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 under investigation for the treatment of rare skin keratodermas.
For additional information, please visit www.sol-gel.com.
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to our expected cash runway. In some cases, you can identify forward-looking statements by terminology such as 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'expect,' 'predict,' 'potential,' or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management's current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators' ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators' ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators' ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ('SEC') on April 29, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.
SOL-GEL TECHNOLOGIES LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Unaudited)
December 31,
March 31,
2024
2025
Assets
CURRENT ASSETS:
Cash and cash equivalents
$
19,489
$
16,890
Bank deposits
12
12
Marketable securities
4,425
-
Accounts receivables
3,595
3,883
Prepaid expenses and other current assets
3,774
2,647
TOTAL CURRENT ASSETS
31,295
23,432
NON-CURRENT ASSETS:
Restricted long-term deposits and cash equivalents
1,291
1,293
Long-term receivables
1,024
518
Property and equipment, net
202
183
Operating lease right-of-use assets
1,426
1,332
Other long-term assets
13
-
Funds in respect of employee rights upon retirement
595
305
TOTAL NON-CURRENT ASSETS
4,551
3,631
TOTAL ASSETS
$
35,846
$
27,063
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable
$
1,265
$
438
Other accounts payable
3,590
3,702
Current maturities of operating leases
430
433
TOTAL CURRENT LIABILITIES
5,285
4,573
LONG-TERM LIABILITIES:
Operating leases liabilities
878
746
Liability for employee rights upon retirement
833
363
Other long-term Liability
1,209
TOTAL LONG-TERM LIABILITIES
1,711
2,318
TOTAL LIABILITIES
6,996
6,891
SHAREHOLDERS' EQUITY:
Ordinary shares, NIS 0.1 par value – authorized: 5,000,000 as of December 31,
2024 and March 31, 2025, respectively; issued and outstanding: 2,785,762 as of December 31, 2024 and March 31, 2025, respectively (*)
774
774
Additional paid-in capital
258,959
259,089
Accumulated deficit
(230,883)
(239,691)
TOTAL SHAREHOLDERS' EQUITY
28,850
20,172
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$
35,846
$
27,063
(*) All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split.
SOL-GEL TECHNOLOGIES LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands)
(Unaudited)
Three months endedMarch 31
2024
2025
LICENSE REVENUES
$
466
$
1,031
RESEARCH AND DEVELOPMENT EXPENSES
5,345
8,843
GENERAL AND ADMINISTRATIVE EXPENSES
1,833
1,257
OPERATING LOSS
6,712
9,069
FINANCIAL INCOME,net
(368)
(261)
LOSS FOR THE PERIOD
6,344
8,808
BASIC AND DILUTED LOSS PER ORDINARY SHARE
2.3
3.2
WEIGHTED AVERAGE NUMBER OF
SHARES*OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (*)
2,785,762
2,785,762
(*)All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split.
Sol-Gel Contact:Eyal Ben-OrChief Financial Officerir@sol-gel.com+972-8-9313429Source: Sol-Gel Technologies Ltd.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Investors in Kandi Technologies Group (NASDAQ:KNDI) have unfortunately lost 69% over the last five years
While it may not be enough for some shareholders, we think it is good to see the Kandi Technologies Group, Inc. (NASDAQ:KNDI) share price up 17% in a single quarter. But that doesn't change the fact that the returns over the last half decade have been disappointing. In that time the share price has delivered a rude shock to holders, who find themselves down 69% after a long stretch. So we're hesitant to put much weight behind the short term increase. We'd err towards caution given the long term under-performance. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Kandi Technologies Group isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. In the last half decade, Kandi Technologies Group saw its revenue increase by 3.9% per year. That's far from impressive given all the money it is losing. It's likely this weak growth has contributed to an annualised return of 11% for the last five years. We'd want to see proof that future revenue growth is likely to be significantly stronger before getting too interested in Kandi Technologies Group. When a stock falls hard like this, some investors like to add the company to a watchlist (in case the business recovers, longer term). The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time. A Different Perspective Investors in Kandi Technologies Group had a tough year, with a total loss of 31%, against a market gain of about 16%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 11% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Kandi Technologies Group better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Kandi Technologies Group , and understanding them should be part of your investment process. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Which Is the Best "Magnificent Seven" Stock to Buy Right Now?
Key Points This dominant internet enterprise is already positioned as a leader in the AI race, with popular products and services, a cloud platform, and chips. There are few companies that have the financial firepower that this one does, letting it always operate from a position of strength. Despite being a high-quality business, shares trade at a below-market valuation multiple. 10 stocks we like better than Alphabet › Before, it was the FAANG stocks. In recent years, the term "Magnificent Seven" was used to group what the market believes are some of most dominant businesses on Earth. These companies' shares soared, a key factor putting them in investors' good graces. But among these elite businesses, which one is the best Magnificent Seven stock that investors should buy right now? The answer is as clear as day. Dominant internet enterprise operating from a position of strength The Magnificent Seven stock that investors should buy today is Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG). As artificial intelligence (AI) alters how people search for and obtain information, there have been real worries that this internet giant's competitive position is under attack. However, I don't think investors should worry. Google Search is Alphabet's bread and butter, raking in $50.7 billion in revenue in the first quarter. That figure was up 9.7% year over year and 25.5% higher than exactly two years ago despite the rise of OpenAI's ChatGPT. CEO Sundar Pichai says that the AI Overviews feature is "going very well with over 1.5 billion users per month." Alphabet operates from a position of power because it has "15 products that each serve half a billion people, and six that serve over 2 billion each," according to Pichai. No company has this type of reach and broad adoption, giving Alphabet a unique advantage with its distribution capabilities to introduce new AI features. And for what it's worth, Google Gemini is already integrated into these offerings. Alphabet is in a position to be a leading AI company, at least when it comes to serving individual users out there. However, the business is also poised to be an AI powerhouse from an enterprise perspective thanks to Google Cloud. Specifically, the Vertex AI platform lets customers build and deploy their own Generative AI applications. This invaluable offering looks to be a mission-critical partner for customers that don't want to get left behind in the AI race. Besides Google Cloud making Alphabet a major player at the AI platform layer, the company is also working on infrastructure. Alphabet is developing tensor processing units (TPUs), its custom-built chips made to handle inference at a larger scale. "It delivers more than 10 (times) improvement in compute power over our recent high-performance TPU, while being nearly twice as power efficient," Pichai claimed on the Q1 2025 earnings call. With deep pockets ($95 billion in cash, cash equivalents, and marketable securities as of March 31), Alphabet has what it takes to play offense and keep its foot on the gas pedal. The company plans to spend a whopping $75 billion in capital expenditures this year to buttress its technological infrastructure and build servers and data centers. We haven't even mentioned YouTube yet, which might get overshadowed by the market's focus on AI. According to data from Nielsen, YouTube commands the most daily TV viewing time in the U.S. among any streaming rival, well ahead of Netflix. This video platform also benefits from a powerful network effect, with the service becoming more valuable as the number of content creators and viewers grows. Bargain hiding in plain sight It's reasonable for investors to think that the best opportunities come from smaller companies whose stocks fly under the radar. This just isn't the case, though. Alphabet is the perfect example of a bargain that's hiding in plain sight. Yes, it carries a massive $2.2 trillion market cap. And it did bring in $350 billion in revenue in 2024. However, its valuation is compelling. As of July 15, the stock trades at a price-to-earnings (P/E) ratio of just 20.3. This represents a discount to the overall S&P 500. And it makes Alphabet the cheapest stock of all the Magnificent Seven businesses, supporting the argument that this company should be in your portfolio. Should you buy stock in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Netflix. The Motley Fool has a disclosure policy. Which Is the Best "Magnificent Seven" Stock to Buy Right Now? was originally published by The Motley Fool Sign in to access your portfolio
CNBC
an hour ago
- CNBC
If Apple makes a foldable phone, analysts say this stock will benefit
Even if Apple's long-awaited foldable may still be months or years away, buyers are lining up for a potential major supplier: Chinese glass maker Lens Technology . It's "one of the key beneficiaries of [the] foldable iOS smartphone supply chain," Citi analysts led by Kyna Wong said in a July 14 report about Lens Tech. They estimate the device could contribute to 5% of the Chinese company's revenue next year, and 12% in 2027. In a report last week, reputable Apple analyst Ming-Chi Kuo kept up expectations that the iPhone maker will begin making a foldable next year. Apple has not made any announcements, and did not immediately respond to a request for comment on whether Lens Tech would provide the "ultra thin glass" that covers the phone display panel. The Citi report initiated coverage of Lens Tech after its stand out Hong Kong public offering on July 9 — raising 4.77 billion HKD ($610 million) on the exchange's busiest day ever for listings — five IPOs at once. Bank of America Securities was one of the underwriters. The Citi analysts rate Lens Tech a buy, with a price target of 26 HKD ($3.13), or nearly 25% upside from Friday's close. "We believe the H-share listing is positive for the company," the analysts said, "as it should provide more cash for potential R & D initiatives and overseas capacity expansion, and expand the overseas institutional investor base." U.S. hedge fund magnate Steve Cohen has jumped in, with multiple purchases over three days that brought his stake in Lens Tech to 8.41% of issued voting shares, according to filings with the Hong Kong stock exchange. About 30% of proceeds raised from the Hong Kong offering will go towards developing foldable screens, Lens Tech said in its prospectus. "By increasing our production capacity in China, we aim to ensure robust support for the mass production of middle and high-end foldable smartphones for our customers and improve our market share in foldable screens," the company said. Lens Tech did not name Apple, but disclosed that its largest customer has been a Nasdaq-listed U.S. multinational founded in 1976 — and said the business relationship started "almost two decades ago when Customer/Supplier A was developing the industry's first touch-enabled smartphone with full-sized screen." Lens Tech's latest listing follows a trend this year of more mainland Chinese companies going public in Hong Kong, which is easier for international investors to access. The company already trades on the Shenzhen Exchange. "We expect Lens to benefit from the foldable iPhone launch [and] AI glasses & robotics" that drive earnings growth of at least 20% a year in 2026 and 2027, UBS analyst Zoe Xu and a team said in a separate July 14 report. They resumed coverage of the mainland China-traded shares with a buy rating and a new price target of 26.20 yuan, up from 16 yuan previously. The Citi analysts also raised their price target on Lens Tech's mainland-traded shares to 32 yuan ($4.45) from 25 yuan. Lens Tech has been reducing its reliance on Apple revenue, and states in its prospectus that "Customer B" is a "Nasdaq-listed American company founded in 2003 that designs and sells smart vehicles." Other listed customers include South Korean, French and Chinese companies. The UBS analysts pointed out that Lens Tech shares remain depressed after a 30% tumble in the week following U.S. "Liberation Day" tariffs in early April. But they expect the company can benefit from selling to Chinese startups such as smart glasses company Rokid and Zhiyuan Robotics. And even without a potential foldable iPhone, Lens Tech can likely benefit from selling cover glass for this year's iPhone 17 which is expected to offer a slimmer design. Lens Tech noted in its prospectus that its direct exports to the U.S. are limited and that it plans to use Hong Kong listing proceeds to expand production overseas in Vietnam and Thailand. In addition to China, the company said it already has factories in Vietnam and Mexico. — CNBC's Michael Bloom contributed to this report.
